All That Glitters Isn’t Gold
By Osagie K. Obasogie and Troy Duster,
The Hastings Center Report
| 10. 12. 2011
The increasing use of DNA evidence has revolutionized criminal investigations. Over the past several years, DNA forensics—once thought to be a less reliable identifier than other forensic techniques, such as latent fingerprinting—have now become the evidentiary gold standard in criminal prosecutions. At the same time, non-DNA-based forensic techniques that have incarcerated thousands are coming under fire.
The policy implications of this shifting dynamic—what Michael Lynch and colleagues call an “inversion of credibility”[1]—can be most clearly seen in the National Research Council’s 2009 report, Strengthening Forensic Science in the United States: A Path Forward. Conducted at Congress’s request by a highly esteemed committee, this report—over three hundred pages—assesses the current state of forensic science.
The committee found remarkable shortcomings in what they call the forensic science knowledge base, noting that the scientific theories and methods used to substantiate many forensic claims frequently cannot withstand close scrutiny. They found an alarmingly “wide variability in capacity, oversight, staffing,
certification, and accreditation.”[2] For example, lack of transparency, susceptibility to bias, and questionable methodologies for friction ridge analyses (analyses of the prints left by...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...